Moderna’s Next Shot.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): BLUESTEN, ADAM (AUTHOR)
  • Source:
    Fast Company. Summer2023, Issue 257, p14-20. 5p. 3 Color Photographs.
  • Additional Information
    • Subject Terms:
      WOMEN patients; BUSINESS enterprises; EMPLOYEE affinity groups; BOOSTER vaccines; HEART diseases in women; CANCER vaccines
    • Abstract:
      Producing Producin a lifesaving vaccine cine to help stanch sta a global pandemic demic might be enough for a regular company.company But there's no indication dication that Bancel - and Ba his company's pany's investors - will investors be satisfied with that. For investors, who sent the company's market cap skyrocketing from roughly $6 billion in 2019 to $196 billion at its peak in August 2021 (it's now back at a more earthbound $50 billion), the company needs to prove that it's not a one-shot wonder, or even "just" a vaccine maker. Today, the company co says that it has 47 drug or vaccine candidates in development, development with three dozen in active clinical clinica trials. UP FRONT "SCIENCE DOESN'T move in a straight line", says Stéphane Bancel, "especially with cutting-edge science that no human has done before you.". [Extracted from the article]
    • Abstract:
      Copyright of Fast Company is the property of Mansueto Ventures LLC and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)